To assess the effect of the PI3K inhibitor on sorafenib resistance in vivo, a subcutaneous xenograft model was used, and the results revealed that PI3K inhibition synergized with sorafenib, reducing tumor weight, tumor volume (Fig. 6D–F) and Ki67 proliferation index, with parallel G6PD suppression versus monotherapy (Fig. 6G). Here, G6PD is linked to neoplasm.